169 related articles for article (PubMed ID: 30034621)
1. Frequent
Tanaka A; Ishikawa S; Ushiku T; Yamazawa S; Katoh H; Hayashi A; Kunita A; Fukayama M
Oncotarget; 2018 Jun; 9(50):29336-29350. PubMed ID: 30034621
[TBL] [Abstract][Full Text] [Related]
2. The Significance of the
Zhang WH; Zhang SY; Hou QQ; Qin Y; Chen XZ; Zhou ZG; Shu Y; Xu H; Hu JK
Front Oncol; 2020; 10():1214. PubMed ID: 32983960
[No Abstract] [Full Text] [Related]
3. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
Nakayama I; Shinozaki E; Sakata S; Yamamoto N; Fujisaki J; Muramatsu Y; Hirota T; Takeuchi K; Takahashi S; Yamaguchi K; Noda T
Cancer Sci; 2019 Apr; 110(4):1352-1363. PubMed ID: 30771244
[TBL] [Abstract][Full Text] [Related]
4. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
Zhang F; Sahu V; Peng K; Wang Y; Li T; Bala P; Aitymbayev D; Sahgal P; Schaefer A; Der CJ; Ryeom S; Yoon S; Sethi N; Bass AJ; Zhang H
Gut; 2024 Apr; ():. PubMed ID: 38621923
[TBL] [Abstract][Full Text] [Related]
5. RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach.
Hashimoto T; Ogawa R; Tang TY; Yoshida H; Taniguchi H; Katai H; Oda I; Sekine S
Mod Pathol; 2019 Apr; 32(4):568-575. PubMed ID: 30425335
[TBL] [Abstract][Full Text] [Related]
6. RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer.
Yang H; Hong D; Cho SY; Park YS; Ko WR; Kim JH; Hur H; Lee J; Kim SJ; Kwon SY; Lee JH; Park DY; Song KS; Chang H; Ryu MH; Cho KS; Kang JW; Kook MC; Thiessen N; He A; Mungall A; Han SU; Kim HK
Nat Commun; 2018 Oct; 9(1):4439. PubMed ID: 30361512
[TBL] [Abstract][Full Text] [Related]
7. Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity.
Yao F; Kausalya JP; Sia YY; Teo AS; Lee WH; Ong AG; Zhang Z; Tan JH; Li G; Bertrand D; Liu X; Poh HM; Guan P; Zhu F; Pathiraja TN; Ariyaratne PN; Rao J; Woo XY; Cai S; Mulawadi FH; Poh WT; Veeravalli L; Chan CS; Lim SS; Leong ST; Neo SC; Choi PS; Chew EG; Nagarajan N; Jacques PÉ; So JB; Ruan X; Yeoh KG; Tan P; Sung WK; Hunziker W; Ruan Y; Hillmer AM
Cell Rep; 2015 Jul; 12(2):272-85. PubMed ID: 26146084
[TBL] [Abstract][Full Text] [Related]
8. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases.
Ushiku T; Ishikawa S; Kakiuchi M; Tanaka A; Katoh H; Aburatani H; Lauwers GY; Fukayama M
Gastric Cancer; 2016 Apr; 19(2):403-411. PubMed ID: 25823974
[TBL] [Abstract][Full Text] [Related]
9. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K; Ushiku T; Urabe M; Fukuyo M; Abe H; Ishikawa S; Seto Y; Aburatani H; Hamakubo T; Kaneda A; Fukayama M
Oncotarget; 2016 Sep; 7(39):64168-64181. PubMed ID: 27580354
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer.
Shu Y; Zhang W; Hou Q; Zhao L; Zhang S; Zhou J; Song X; Zhang Y; Jiang D; Chen X; Wang P; Xia X; Liao F; Yin D; Chen X; Zhou X; Zhang D; Yin S; Yang K; Liu J; Fu L; Zhang L; Wang Y; Zhang J; An Y; Cheng H; Zheng B; Sun H; Zhao Y; Wang Y; Xie D; Ouyang L; Wang P; Zhang W; Qiu M; Fu X; Dai L; He G; Yang H; Cheng W; Yang L; Liu B; Li W; Dong B; Zhou Z; Wei Y; Peng Y; Xu H; Hu J
Nat Commun; 2018 Jun; 9(1):2447. PubMed ID: 29961079
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer.
Kim SR; Shin K; Park JM; Lee HH; Song KY; Lee SH; Kim B; Kim SY; Seo J; Kim JO; Roh SY; Kim IH
J Gastric Cancer; 2020 Dec; 20(4):408-420. PubMed ID: 33425442
[TBL] [Abstract][Full Text] [Related]
12. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas.
Pellino A; Brignola S; Riello E; Niero M; Murgioni S; Guido M; Nappo F; Businello G; Sbaraglia M; Bergamo F; Spolverato G; Pucciarelli S; Merigliano S; Pilati P; Cavallin F; Realdon S; Farinati F; Dei Tos AP; Zagonel V; Lonardi S; Loupakis F; Fassan M
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834447
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
Yan HHN; Siu HC; Law S; Ho SL; Yue SSK; Tsui WY; Chan D; Chan AS; Ma S; Lam KO; Bartfeld S; Man AHY; Lee BCH; Chan ASY; Wong JWH; Cheng PSW; Chan AKW; Zhang J; Shi J; Fan X; Kwong DLW; Mak TW; Yuen ST; Clevers H; Leung SY
Cell Stem Cell; 2018 Dec; 23(6):882-897.e11. PubMed ID: 30344100
[TBL] [Abstract][Full Text] [Related]
16. Claudins and Gastric Cancer: An Overview.
Hashimoto I; Oshima T
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053454
[TBL] [Abstract][Full Text] [Related]
17. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype.
Watari J; Saitoh Y; Fujiya M; Shibata N; Tanabe H; Inaba Y; Okamoto K; Maemoto A; Ohta T; Yasuda A; Ayabe T; Ashida T; Yokota K; Obara T; Kohgo Y
J Gastroenterol; 2004; 39(2):104-12. PubMed ID: 15069616
[TBL] [Abstract][Full Text] [Related]
18. DGC-specific
Nishizawa T; Nakano K; Harada A; Kakiuchi M; Funahashi SI; Suzuki M; Ishikawa S; Aburatani H
Oncotarget; 2018 May; 9(33):23198-23207. PubMed ID: 29796182
[No Abstract] [Full Text] [Related]
19. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.
Sahin U; Koslowski M; Dhaene K; Usener D; Brandenburg G; Seitz G; Huber C; Türeci O
Clin Cancer Res; 2008 Dec; 14(23):7624-34. PubMed ID: 19047087
[TBL] [Abstract][Full Text] [Related]
20. Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypes.
Wagner P; Gass P; Pöschke P; Eckstein M; Gloßner L; Hartmann A; Beckmann MW; Fasching PA; Ruebner M; Emons J; Erber R
Virchows Arch; 2024 Feb; ():. PubMed ID: 38326579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
